HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shark cartilage monograph

This article was originally published in The Tan Sheet

Executive Summary

Institute of Medicine is requesting written comments on 1draft prototype monograph for shark cartilage by Oct. 6. Committee on the Framework for Evaluating the Safety of Dietary Supplements and its consultants will meet Oct. 7-8 to consider comments. Monograph, which was released Sept. 18, includes a description of dietary supplement preparations, amount ingested in ordinary use, human safety data, animal studies, sources of potential contamination and conditions of use suggested or recommended in labeling. IoM released a draft monograph on chaparral in August (2"The Tan Sheet" Sept. 9, 2002, p. 8). Committee also is scheduled to hold a public meeting Sept. 26 in Washington, D.C...

You may also be interested in...



Chaparral AER Data Resembles Kava Reports, CRN’s Cardellina Says

Adverse event reports on chaparral have certain parallels with those that have been filed for kava, according to Council for Responsible Nutrition VP-Botanical Science & Regulatory Affairs John Cardellina, PhD

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel